Worth mentioning is the frequently observed overexpression of CD133 in MLL-AF4-rearranged B-ALL patients, which is in line with the results of recent studies that revealed that PROM1, the corresponding CD133 gene, is a direct target of MLL-AF4 gene regulation [23]. Here, KMT2A is linked to acute lymphoblastic leukemia.